PSA-progression only in high-risk, metastatatic hormone-sensitive prostate cancer patients treated with abiraterone in the LATITUDE trial.
Por:
Lorente D, Romero N, Lozano R, Novella S, Montes A, Mateo J, Castro E, Sanchez A, Olmos D
Publicada:
20 feb 2022
Resumen:
|